Accueil   Diary - News   All news ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer

ERYTECH Completes Patient Enrollment in Phase 2 Trial of eryaspase (GRASPA®) for Pancreatic Cancer

Logo ERYTECH JPEGPrimary data read-out from the trial expected by early 2017

 

ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), a French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the final patient has been enrolled in its Phase 2 trial of eryaspase, also known as ERY-ASP or GRASPA®, for the treatment of pancreatic cancer.

 

The multicenter, randomized Phase 2 trial is evaluating eryaspase as a second-line treatment of patients with metastatic pancreatic cancer. In the study conducted in France, eryaspase was added to the standard of care (currently Gemcitabine or FOLFOX regimen) and then compared to the standard of care alone in a 2-to-1 randomization. The primary endpoint of the trial is progression-free survival (PFS) at four months.

 

The trial has completed enrollment of 139 patients and we expect to report primary results from this trial by early 2017.

 



Read the press release